Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells

Science

Volumn 277, Issue 5334, 1997, Pages 2005-2007

  Sallusto, Federica ^a   Mackay, Charles R ^b,c   Lanzavecchia, Antonio ^a  

^a BASEL INSTITUTE FOR IMMUNOLOGY   (Switzerland)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c Millennium BioTherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 5; T LYMPHOCYTE RECEPTOR;

ANTIBODY LABELING; ARTICLE; BASOPHIL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; EOSINOPHIL; HELPER CELL; HUMAN; HUMAN CELL; INFLAMMATION; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION;

ADULT; CALCIUM; CELL LINE; CELL SEPARATION; CHEMOKINES, CC; CHEMOTAXIS, LEUKOCYTE; CLONE CELLS; CYTOKINES; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKIN-3; INTERLEUKIN-4; RECEPTORS, CHEMOKINE; RECEPTORS, CYTOKINE; TH2 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030769920     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.277.5334.2005     Document Type: Article

References (42)

1. T. A. Springer, Nature 346, 425 (1990); E. C. Butcher and L. J. Picker, Science 272, 60 (1996).
2. T. A. Springer, Nature 346, 425 (1990); E. C. Butcher and L. J. Picker, Science 272, 60 (1996).
3. M. Baggiolini, B. Dewald, B. Moser, Annu. Rev. Immunol. 15, 675 (1997).
4. E. C. Butcher, Cell 67, 1033 (1991); T. A. Springer, ibid. 76, 301 (1994).
5. E. C. Butcher, Cell 67, 1033 (1991); T. A. Springer, ibid. 76, 301 (1994).
6. T. R. Mosmann and R. L. Coffman, Annu. Rev. Immunol. 7, 145 (1989); S. Romagnani, ibid. 12, 227 (1994).
7. T. R. Mosmann and R. L. Coffman, Annu. Rev. Immunol. 7, 145 (1989); S. Romagnani, ibid. 12, 227 (1994).
8. F. Austrup et al., Nature 385, 81 (1997).
9. J.-A. Gonzalo et al., Immunity 4, 1 (1996).
10. P. D. Ponath et al., J. Clin. Invest. 97, 604 (1996); P. J. Jose et al., J. Exp. Med. 179, 881 (1994); M. Kitaura et al., J. Biol. Chem. 271, 7725 (1996); E. A. Garcia-Zepeda et al., Nature Med. 2, 449 (1996).
11. P. D. Ponath et al., J. Clin. Invest. 97, 604 (1996); P. J. Jose et al., J. Exp. Med. 179, 881 (1994); M. Kitaura et al., J. Biol. Chem. 271, 7725 (1996); E. A. Garcia-Zepeda et al., Nature Med. 2, 449 (1996).
12. P. D. Ponath et al., J. Clin. Invest. 97, 604 (1996); P. J. Jose et al., J. Exp. Med. 179, 881 (1994); M. Kitaura et al., J. Biol. Chem. 271, 7725 (1996); E. A. Garcia-Zepeda et al., Nature Med. 2, 449 (1996).
13. P. D. Ponath et al., J. Clin. Invest. 97, 604 (1996); P. J. Jose et al., J. Exp. Med. 179, 881 (1994); M. Kitaura et al., J. Biol. Chem. 271, 7725 (1996); E. A. Garcia-Zepeda et al., Nature Med. 2, 449 (1996).
14. B. L. Daugherty et al., J. Exp. Med. 183, 2349 (1996); P. D. Ponath et al., ibid., p. 2437; M. G. Uguccioni et al., J. Clin. Invest., in press.
15. B. L. Daugherty et al., J. Exp. Med. 183, 2349 (1996); P. D. Ponath et al., ibid., p. 2437; M. G. Uguccioni et al., J. Clin. Invest., in press.
16. B. L. Daugherty et al., J. Exp. Med. 183, 2349 (1996); P. D. Ponath et al., ibid., p. 2437; M. G. Uguccioni et al., J. Clin. Invest., in press.
17. H. S. Heath et al., J. Clin. Invest. 99, 178 (1997).
18. + cells (25).
19. -7 M phorbol 12-myristate 13-acetate (PMA). Cytokine production was measured in the 24-hour culture supernatant by enzyme-linked immunosorbent assay (ELISA), using matched pairs of antibodies specific for IL-2, IL-4, IL-5, IL-10, tumor necrosis factor-α (TNF-α), TNF-β, and IFN-γ (PharMingen, San Diego, CA).
20. -7 M PMA plus ionomycin (1 μg/ml) for 4 hours. Brefeldin A (10 μg/ml) was added during the last 2 hours. Cells were fixed with 2% paraformaldehyde, permeabilized with phosphate-buffered saline containing fetal bovine serum (1%) and saponin (0.5%) and stained with fluorescein isothiocyanate (FITC)-labeled anti-IFN-γ (IgG1) and phycoerythrin (PE)-labeled anti-IL-4 (IgG2b) monoclonal antibodies (Becton Dickinson, Mountain View, CA). In some experiments, the cells were stained, before permeabilization, with anti-CD4 (BL4, IgG2a, Immunotech, Marseille, France) or anti-CD8 (OKT8, IgG2a, American Type Culture Collection), then with biotin-labeled goat anti-mouse IgG2a (Southern Biotechnology, Birmingham, AL) and streptavidin-tricolor (Molecular Probes, Eugene, OR). Because T cell activation results in a rapid down-regulation of CCR3, it is not possible to assess CCR3 expression and intracellular cytokines simultaneously.
21. + cells. Results comparable to those in Fig. 1 were obtained in sorted cell lines obtained from two healthy and three atopic individuals. In three out of five cases the CCR3-depleted cells produced lower concentrations of IL-4 and IL-5 than the unsorted cells. No clear differences were found in the production of IL-10, IFN-γ, IL-2, TNF-α, or TNF-β, or between healthy and atopic donors. A correlation between CCR3 expression and production of IL-4 but not IFN-γ was observed in 13 antigen-specific T cell clones (14).
22. F. Sallusto, unpublished data.
23. H2-polarizing conditions.
24. H2-polarizing conditions.
25. H2-polarizing conditions.
26. H2-polarizing conditions.
27. H2-polarizing conditions.
28. L. Rogge et al., J. Exp. Med. 185, 825 (1997).
29. S. Sad and T. R. Mosmann, J. Immunol. 153, 3514 (1994).
30. S. Valitutti, M. Dessing, K. Aktories, H. Gallati, A. Lanzavecchia, J. Exp. Med. 181, 577 (1995). T cell clones were loaded with Indo-1 AM (Sigma) and analyzed on a Coulter Elite Flow Cytometer (Coulter Electronics, Hialeah, FL).
31. C. R. MacKay, unpublished data. Chemotaxis experiments were done as described by P. D. Ponath et al. (7), with a transendothelial assay and eotaxin or MCP-1 at 10 nM and IP-10 at 20 nM. Cells migrating to the bottom of the transwell chemotaxis chamber were counted by flow cytometry.
32. A. H. Lichtman and A. K. Abbas, Curr. Biol. 7, 242 (1997).
33. Eotaxin is not the only agonist for CCR3, because MCP-3, MCP-4, RANTES (2), and eotaxin 2 [U. Forrsmann et al., J. Exp. Med. 185, 2171 (1997)] can also bind and trigger CCR3.
34. C. J. Corrigan and A. B. Kay, Immunol. Today 13, 501 (1992); J. M. Drazen, J. P. Arm, K. F. Austen, J. Exp. Med. 183, 1 (1996).
35. C. J. Corrigan and A. B. Kay, Immunol. Today 13, 501 (1992); J. M. Drazen, J. P. Arm, K. F. Austen, J. Exp. Med. 183, 1 (1996).
36. + T cells express CCR3.
37. D. S. Robinson et al., N. Engl. J. Med. 326, 298 (1992); G. F. Del Prete et al., Eur. J. Immunol. 23, 1445 (1993); S. H. Gavett, X. Chen, F. Finkelman, M. Wills Karp, Am. J. Respir. Cell. Mol. Biol. 10, 587 (1994).
38. D. S. Robinson et al., N. Engl. J. Med. 326, 298 (1992); G. F. Del Prete et al., Eur. J. Immunol. 23, 1445 (1993); S. H. Gavett, X. Chen, F. Finkelman, M. Wills Karp, Am. J. Respir. Cell. Mol. Biol. 10, 587 (1994).
39. D. S. Robinson et al., N. Engl. J. Med. 326, 298 (1992); G. F. Del Prete et al., Eur. J. Immunol. 23, 1445 (1993); S. H. Gavett, X. Chen, F. Finkelman, M. Wills Karp, Am. J. Respir. Cell. Mol. Biol. 10, 587 (1994).
40. F. Sallusto and C. R. MacKay, unpublished data.
41. F. Sallusto and A. Lanzavecchia, J. Exp. Med. 179, 1109 (1994).
42. We thank A. Mari and F. Nestle for providing samples from allergic patients; M. Dessing and A. Pickert for cell sorting; D. Lenig and H. Heath for expert technical assistance; and M. Cella, M. Colonna, and M. Kopf for critical reading and comments. The Basel Institute for Immunology was founded and is supported by F. Hoffmann-La Roche Ltd., Basel, Switzerland. F. S. is also with the department of immunology, Istituto Superiore de Sanità, Rome.